In April 2022, Saladax Biomedical, Inc. acquired a patent portfolio for antipsychotic drug testing from Janssen Pharmaceutica NV. The IP portfolio includes the 17 patent families and has resulted in 33 US and 296 patents in ex-U.S. countries. With this IP portfolio, Saladax develops tests for chemistry analyzers commonly found in hospitals and a point-of-care instrument that can be used where centralized testing is not possible. With this acquisition, Saladax Biomedical has strengthened its position in the
drug testing space.